Webcast ImageWebcast
Q2 2017 Laboratory Corporation of America Holdings Earnings Conference Call (Live)
07/26/17 at 9:00 a.m. ET
E-mail Alerts Receive E-mail Alerts | RSS RSS Feeds
Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
07/19/17LabCorp Introduces New ADAMTS13 Test for Rare Life-Threatening Blood Clot Disorder
LabCorp’s Proprietary Assay Offers Faster, More Accurate Diagnosis to Help Patients Receive Most-Appropriate Therapy BURLINGTON, N.C.--(BUSINESS WIRE)--Jul. 19, 2017-- LabCorp® (NYSE: LH) has begun offering its new, proprietary ADAMTS13 test to distinguish diseases characterized by life-threatening, acute thrombotic microangiopathy (TMA). TMA is a relatively rare but serious syndrome in which small blood vessels develop blood clots, which result ... 
Printer Friendly Version
07/18/17LabCorp’s William Hanlon Appointed to Governing Committee of the National Evaluation System for health Technology Coordinating Center
BURLINGTON, N.C.--(BUSINESS WIRE)--Jul. 18, 2017-- LabCorp® (NYSE: LH), a leading global life sciences company, announced today that the National Evaluation System for health Technology Coordinating Center (NESTcc) has appointed William (Bill) Hanlon, Ph.D., chief development officer and head of Global Regulatory Affairs for its Covance Drug Development business, to serve on its Governing Committee. The Medical Device Innovation Consortium (MDIC), a publ... 
Printer Friendly Version
07/11/17LabCorp and Novant Health Extend Laboratory Services Agreement
Extension Demonstrates Value of LabCorp’s Health System Collaborations BURLINGTON, N.C.--(BUSINESS WIRE)--Jul. 11, 2017-- LabCorp® (NYSE: LH) and Novant Health have agreed to a multi-year extension of their Technical Services Agreement, which was first implemented in 2012. Under the agreement, LabCorp Diagnostics provides Novant Health with laboratory management services for all Novant Health acute care facilities. In addition to the T... 
Printer Friendly Version
07/03/17Conversion Right Triggered for LabCorp’s Zero Coupon Convertible Subordinated Notes Due 2021
BURLINGTON, N.C.--(BUSINESS WIRE)--Jul. 3, 2017-- LabCorp® (NYSE: LH) announced today that its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) may be converted as set forth below. The Zero Coupon Notes are convertible into cash and Common Stock of LabCorp, if any, subject to the terms of the Zero Coupon Notes and the Indenture, dated as of October 24, 2006 between LabCorp and The Bank of New York Mellon, as trustee ... 
Printer Friendly Version
06/28/17Walgreens and LabCorp Collaborate to Bring Patient Service Centers for Laboratory Testing to Select Walgreens Stores
"LabCorp at Walgreens" Sites Will Provide Specimen Collection Services for LabCorp Testing Seven Service Centers Planned to Open at Walgreens Stores in 2017 DEERFIELD, Ill. & BURLINGTON, N.C.--( BUSINESS WIRE )--Walgreens and LabCorp® (NYSE: LH) today announced a collaboration through which LabCorp will develop and operate patient service centers within select Walgreens stores. The centers, which will be co-branded "LabCorp at Walgreens," will offer LabCorp patie... 
Printer Friendly Version
06/14/17Covance Opens State-of-the-Art Laboratory for Companion Diagnostics
Dedicated Facility Furthers the Unmatched Value of the Combined Expertise of Covance Drug Development and LabCorp Diagnostics to Advance Precision Medicine BURLINGTON, N.C.--(BUSINESS WIRE)--Jun. 14, 2017-- LabCorp® (NYSE:LH), a leading global life sciences company, announced today that its Covance Drug Development (Covance) business will extend its capabilities in precision medicine by opening a dedicated, state-of-the-art companion diagnosti... 
Printer Friendly Version
05/23/17LabCorp Exclusively Launches Sera Prognostics’ PreTRM Test to Assess for Risk of Preterm Birth
The PreTRM Test is the Only Validated Test That Provides Early and Individualized Evaluation of Preterm Birth Risk BURLINGTON, N.C.--(BUSINESS WIRE)--May 23, 2017-- LabCorp® (NYSE: LH) today announced the nationwide availability of the PreTRM® test. Developed by Sera Prognostics, Inc., the PreTRM test is the first of its kind validated blood test that provides an early and individualized prediction of preterm birth risk for pregnant women. Lab... 
Printer Friendly Version
05/09/17LabCorp is Scheduled to Present at the Bank of America Merrill Lynch 2017 Health Care Conference
BURLINGTON, N.C.--(BUSINESS WIRE)--May 9, 2017-- LabCorp® (NYSE: LH) today announced it will participate at the Bank of America Merrill Lynch 2017 Health Care Conference. LabCorp’s presentation is scheduled for Tuesday, May 16, 2017, at 10:40 a.m. PT. A live audio webcast of the presentation will be available via the Company website at www.labcorp.com and archived for replay. About LabCorp LabCorp (NYSE: LH), an S&am... 
Printer Friendly Version
05/04/17LabCorp Completes Acquisition of Pathology Associates Medical Laboratories
Transaction Establishes Relationships with Community-Based Health Systems Across Multiple StatesBURLINGTON, N.C. & RENTON, Wash. & ENGLEWOOD, Colo.--(BUSINESS WIRE)--LabCorp® (NYSE:LH) has completed the acquisition of Pathology Associates Medical Laboratories (PAML) from former owners Providence Health & Services (Providence) and Catholic Health Initiatives (CHI). PAML, based in Spokane, Washington, is one of the nation’s premier medical reference laboratories and a healthcare soluti... 
Printer Friendly Version
05/04/17LabCorp to Webcast Its Annual Meeting of Shareholders
BURLINGTON, N.C.--(BUSINESS WIRE)--May 4, 2017-- LabCorp® (NYSE: LH) today announced that its Annual Meeting of Shareholders will be webcast live beginning May 11, 2017 at 9:00 a.m. Eastern Daylight Time via the Company website at www.labcorp.com. An archived replay of the audio webcast will be available for one year. About LabCorp LabCorp (NYSE: LH), an S&P 500 company, is a leading global life sciences company that is deeply ... 
Printer Friendly Version
05/03/17LabCorp Enhances VistaSeq Hereditary Cancer Test Portfolio with Addition of New Panels and New Genes That Can Be Assessed
Expanded Test Offering Provides Targeted Insight into Risk for Hereditary Cancer Syndromes BURLINGTON, N.C.--(BUSINESS WIRE)--May 3, 2017-- LabCorp® (NYSE: LH) today announced a significant enhancement to its proprietary VistaSeqSM Hereditary Cancer portfolio, with ten new test panels focusing on the risk of specific hereditary cancer syndromes. The number of cancer genes that can be assessed has also increased to 59 to reflect advances in the... 
Printer Friendly Version
05/01/17LabCorp’s Acquisition of Pathology Associates Medical Laboratories Clears Antitrust Review
BURLINGTON, N.C.--(BUSINESS WIRE)--May 1, 2017-- LabCorp® (NYSE: LH) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, or HSR Act, applicable to LabCorp’s acquisition of Pathology Associates Medical Laboratories, LLC (PAML) has expired. As previously announced, LabCorp, Providence Health & Services (Providence) and Catholic Health Initiatives (CHI) entered into a definitive agreement for LabCorp t... 
Printer Friendly Version
05/01/17LabCorp Completes Acquisition of Assets of Mount Sinai Health System Clinical Outreach Laboratories
Transaction will benefit physicians and patients in metropolitan New York City BURLINGTON, N.C.--(BUSINESS WIRE)--May 1, 2017-- LabCorp® (NYSE: LH), a leading global life sciences company, has completed the previously announced acquisition of assets of the Mount Sinai Health System Clinical Outreach Laboratories. LabCorp is now available to provide comprehensive laboratory services to physicians and patients that previously used Mount Sinai’s ... 
Printer Friendly Version
04/28/17LabCorp to Exclusively Offer the M3 Checklist, a Multi-Condition Mental Health Screening Tool
The M3 Checklist Helps to Identify and Monitor Common Mental Health Conditions in the Primary Care Setting BURLINGTON, N.C. & ROCKVILLE, Md.--(BUSINESS WIRE)--Apr. 28, 2017-- LabCorp® (NYSE:LH) and M-3 Information, LLC today announced the nationwide availability through LabCorp of the peer-reviewed, clinically validated M3 Checklist assessment for mental illness. The M3 Checklist was developed by M3 Information with a goal to reengineer the ... 
Printer Friendly Version
04/25/17Laboratory Corporation of America® Holdings Announces 2017 First Quarter Results and Updates 2017 Guidance
Q1 Net revenue of $2.4 billion, up 5% over last year Q1 Diluted EPS of $1.84, up 16% over last year; Q1 Adjusted EPS of $2.22, up 8% over last year Q1 Free Cash Flow of $162 million, up 188% over last year 2017 Adjusted EPS guidance updated to $9.20 to $9.60, up 4% to 9% over 2016 BURLINGTON, N.C.--(BUSINESS WIRE)--Apr. 25, 2017-- Laboratory Corporation of America® Holdings (Lab... 
Printer Friendly Version
04/21/17Covance to Expand Large-Molecule Development Capabilities in the UK
Covance Drug Development continues to invest in precision medicine with expansion into laboratory space at York facility BURLINGTON, N.C.--(BUSINESS WIRE)--Apr. 21, 2017-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH), a leading global life sciences company, announced today that its Covance Drug Development (Covance) business will expand its biopharmaceutical chemistry, manufacturing and control (BioPharmCMC) capabilities based in... 
Printer Friendly Version
04/03/17Conversion Right Triggered for LabCorp’s Zero Coupon Convertible Subordinated Notes Due 2021
BURLINGTON, N.C.--(BUSINESS WIRE)--Apr. 3, 2017-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) announced today that its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) may be converted as set forth below. The Zero Coupon Notes are convertible into cash and Common Stock of LabCorp, if any, subject to the terms of the Zero Coupon Notes and the Indenture, dated as of October 24, 2006 between LabCorp and T... 
Printer Friendly Version
03/30/17LabCorp Commends Reps. Dr. Bucshon, DeGette for Releasing Bipartisan Discussion Draft of the Diagnostic Accuracy and Innovation Act (DAIA)
BURLINGTON, N.C.--(BUSINESS WIRE)--Mar. 30, 2017-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE:LH), a leading global life sciences company, today issued the following statement regarding a discussion draft of the Diagnostic Accuracy and Innovation Act (DAIA) recently released by Reps. Dr. Larry Bucshon, R-Ind., and Diana DeGette, D-Colo. “LabCorp commends Reps. Dr. Bucshon and DeGette for their leadership in releasing this... 
Printer Friendly Version
03/29/17LabCorp Promotes Executive Gary Huff to CEO of LabCorp Diagnostics, One of the Company’s Two Primary Business Segments
BURLINGTON, N.C.--(BUSINESS WIRE)--Mar. 29, 2017-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE:LH), a leading global life sciences company, today announced that Gary Huff is being promoted to CEO of LabCorp Diagnostics, one of the company’s two primary business segments, effective immediately. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170329005288/en/ Gary Huff... 
Printer Friendly Version
03/13/17LabCorp's Zero Coupon Convertible Subordinated Notes Due 2021 to Accrue Contingent Interest
BURLINGTON, N.C.--(BUSINESS WIRE)--Mar. 13, 2017-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) announced today that for the period of March 12, 2017 to September 11, 2017, its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) will accrue (subject to the terms of the Zero Coupon Notes) contingent cash interest at a rate of no less than 0.125% of the average market price of a Zero Coupon Note for the five trading... 
Printer Friendly Version
03/06/17LabCorp is Scheduled to Present at the 2017 Barclays Global Healthcare Conference
BURLINGTON, N.C.--(BUSINESS WIRE)--Mar. 6, 2017-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) today announced it will participate at the 2017 Barclays Global Healthcare Conference. LabCorp’s presentation is planned for Wednesday, March 15, 2017 at 11:15 AM (ET). A live audio webcast of the presentation will be available via the Company Web site at www.labcorp.com and archived for replay. About LabCorp® ... 
Printer Friendly Version
03/01/17LabCorp is Scheduled to Present at the 38th Annual Raymond James Institutional Investors Conference
BURLINGTON, N.C.--(BUSINESS WIRE)--Mar. 1, 2017-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) today announced it will participate at the 38th Annual Raymond James Institutional Investors Conference. LabCorp’s presentation is scheduled for Tuesday, March 7, 2017 at 11:00 AM (ET). A live audio webcast of the presentation will be available via the Company website at www.labcorp.com and archived for replay. ... 
Printer Friendly Version
02/23/17LabCorp to Acquire Pathology Associates Medical Laboratories from Providence Health & Services and Catholic Health Initiatives
BURLINGTON, N.C. & RENTON, Wash. & ENGLEWOOD, Colo.--(BUSINESS WIRE)--Feb. 23, 2017-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE:LH), Providence Health & Services (Providence) and Catholic Health Initiatives (CHI), today announced that they have entered into a definitive agreement for LabCorp to acquire all of the ownership interest in Pathology Associates Medical Laboratories, LLC, (PAML), one of the nation’s premier medica... 
Printer Friendly Version
02/16/17Laboratory Corporation of America® Holdings Announces Record 2016 Fourth Quarter and Full Year Results and Provides 2017 Guidance
Net Revenue: Q4 of $2.4 billion, up 6% over 2015; Full year of $9.4 billion, up 11% over 2015 Diluted EPS: Q4 of $1.75, up 63% over 2015; Full year of $7.02, up 61% over 2015 Adjusted EPS: Q4 of $2.15, up 9% over 2015; Full year of $8.83, up 12% over 2015 Free Cash Flow: Q4 of $375 million, up 25% over 2015; Full year of $897 million, up 23% over 2015 2017 Adjus... 
Printer Friendly Version
01/10/17LabCorp to Acquire Assets of Mount Sinai Health System Clinical Outreach Laboratories
Transaction will benefit physicians and patients in metropolitan New York City BURLINGTON, N.C.--(BUSINESS WIRE)--Jan. 10, 2017-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH), a world leading life sciences company, and the Mount Sinai Health System (Mount Sinai), one of the largest health systems in metropolitan New York City, have entered into a definitive agreement for LabCorp to acquire assets of Mount Sinai’s Clinical ... 
Printer Friendly Version
01/05/17LabCorp is Scheduled to Present at the 35th Annual J.P. Morgan Healthcare Conference
BURLINGTON, N.C.--(BUSINESS WIRE)--Jan. 5, 2017-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) today announced it will participate at the 35th Annual J.P. Morgan Healthcare Conference. LabCorp’s presentation is scheduled for Tuesday, January 10, 2017 at 1:30 PM (PT). A live audio webcast of the presentation will be available via the Company website at www.labcorp.com and archived for replay. About LabCor... 
Printer Friendly Version
01/04/17Leading Genetic Testing Companies Join Forces to Launch the Coalition for Access to Prenatal Screening
Coalition aims to make noninvasive prenatal testing easily accessible to all pregnant women WASHINGTON, Jan. 4, 2017 /PRNewswire/ -- Today, five leading genetic testing companies in the U.S. are coming together to launch the Coalition for Access to Prenatal Screening (CAPS). This new organization will work to improve access to state-of-the-art prenatal screening using cell-free DNA (cfDNA)-based noninvasive prenatal testing (NIPT). The coalition is comprised of: Ill... 
Printer Friendly Version
01/03/17Conversion Right Triggered for LabCorp’s Zero Coupon Convertible Subordinated Notes Due 2021
BURLINGTON, N.C.--(BUSINESS WIRE)--Jan. 3, 2017-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) announced today that its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) may be converted as set forth below. The Zero Coupon Notes are convertible into cash and Common Stock of LabCorp, if any, subject to the terms of the Zero Coupon Notes and the Indenture, dated as of October 24, 2006 between LabCorp and T... 
Printer Friendly Version
Print Page Print Page | E-mail Page E-mail Page | RSS Feeds RSS Feeds | E-mail Alerts E-mail Alerts | IR Contacts IR Contacts | Financial Tear Sheet Tear Sheet